Pegvisomant in acromegaly: why, when, how

J Endocrinol Invest. 2007 Sep;30(8):693-9. doi: 10.1007/BF03347452.

Authors

A Colao¹, G Arnaldi, P Beck-Peccoz, S Cannavò, R Cozzi, E degli Uberti, L De Marinis, E De Menis, D Ferone, V Gasco, A Giustina, S Grottoli, G Lombardi, P Maffei, E Martino, F Minuto, R Pivonello, E Ghigo

Affiliation

¹ Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Naples, Italy.

PMID: 17923803
DOI: 10.1007/BF03347452

No abstract available

Publication types

Review

MeSH terms

Acromegaly / drug therapy*
Acromegaly / physiopathology
Human Growth Hormone / analogs & derivatives*
Human Growth Hormone / therapeutic use
Humans
Pituitary Gland / physiology

Substances

Human Growth Hormone
pegvisomant